Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Hereditary Cancer in Clinical Practice
Published in: Hereditary Cancer in Clinical Practice 1/2015

Open Access 01-12-2015 | Letter to the Editor

The frequency of BRCA1 founder mutation c.5266dupC (5382insC) in breast cancer patients from Ukraine

Authors: Ielizaveta Gorodetska, Svitlana Serga, Natalia Levkovich, Tetiana Lahuta, Ludmila Ostapchenko, Serhyi Demydov, Nikolay Anikusko, Valeriy Cheshuk, Ivan Smolanka, Svitlana Sklyar, Serhyi Polenkov, Oleksander Boichenko, Iryna Kozeretska

Published in: Hereditary Cancer in Clinical Practice | Issue 1/2015

Login to get access

Abstract

Germ-line mutations in several genes, such as BRCA1 and BRCA2, are known to increase the risk of breast cancer. These heritable mutations are unequally represented among populations with different ethnic background due to founder effects and thereby contribute to differences in breast cancer rates in different populations. The BRCA1 mutation c.5266dupC (also known as 5382insC or 5385insC) was detected in a sample of 193 breast cancer patients in Ukraine by multiplex mutagenically separated PCR using published specific primers. Nine BRCA1 mutations 5382insC were detected (4.7 %). The difference in age of diagnosis (35 years in 5382insC carriers versus 45 years in non-carriers) we observed is consistent with other reports indicating that the 5382insC mutation is a factor of genetic predisposition to breast cancer, which is consistent with reports from other countries.
Literature
1.
O’Donovan PJ, Livingston DM. BRCA1 and BRCA2: Breast/ovarian cancer susceptibility gene products and participants in DNA double-strand break repair. Carcinogenesis. 2010;31:961–7.CrossRefPubMed
2.
Petrucelli N, Daly MB, Feldman GL. Hereditary breast and ovarian cancer due to mutations in BRCA1 and BRCA2. Genet Med. 2010;12:245–59.CrossRefPubMed
3.
Finch A, Beiner M, Lubinski J, Lynch HT, Moller P, Rosen B, et al. Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 Mutation. JAMA. 2006;296(2):185–92.CrossRefPubMed
4.
5.
6.
7.
8.
Saadatmand S, Vos JR, Hooning MJ, Oosterwijk JC, Koppert LB, de Bock GH, et al. Relevance and efficacy of breast cancer screening in BRCA1 and BRCA2 mutation carriers above 60 years: A national cohort study. 2014. doi:10.​1002/​ijc.​28941.
9.
Mostowska A, Pawlik P, Sajdak S, Markowska J, Pawałowska M, Lianeri M, et al. An analysis of polymorphisms within the Wnt signaling pathway in relation to ovarian cancer risk in a Polish population. Mol Diagn Ther. 2014;18:85–91.CrossRefPubMed
10.
11.
12.
Kurian AW, Sigal BM, Plevritis SK. Survival analysis of cancer risk reduction strategies forBRCA1/2mutation carriers. J Clin Oncol. 2010;28:222–31.CrossRefPubMed
13.
Tong A, Kelly S, Nusbaum R, Graves K, Peshkin BN, Valdimarsdottir HB, et al. Intentions for risk-reducing surgery among high-risk women referred for BRCA1/BRCA2 genetic counseling. Psychooncology. 2014. doi:10.​1002/​pon.​3560.
14.
Zakhartseva LM, Gorovenko NG, Podolskaya SV, Anikusko NF, Lobanova OE, Pekur KA, et al. Breast cancer immunohistochemical features in young women with BRCA1/2 mutations. Exp Oncol. 2009;31:174–8.PubMed
15.
Kitsera NI, Shparyk IV, Bilynskyi BT, Tril OV, Mashalyga MS, Oleksyak OO, et al. Analysis of mutations in the genes BCRA1/2 in patients withfamily/hereditary breast cancer which live in the Lviv region (Ukraine). Onkologiia. 2012;11:44–9 (in Ukrainian).
16.
Kruk TV, Peresunko OV, Volkov RA. A molecular genetics study of the types of BRCA1 gene mutations in breast cancer patients and their relatives in the Chernivtsi region of Ukraine. Novoutvorennia. 2012;12:310–4 (in Ukrainian).
17.
Hossein R. Molecular genetic markers of breast cancer in patients of different age groups. PhD thesis. 2012.
18.
Rybchenko LA. Optimization of mutations determination in the BRCA1/2 genes for medical genetic counseling of women about breast cancer. PhD thesis. 2014.
19.
Karami F, Mehdipour P. A comprehensive focus on global spectrum of BRCA1 and BRCA2 mutations in breast cancer. Biomed Res Int. 2013. doi:10.​1155/​2013/​928562.
20.
Navarro de Souza A, Groleau D, Loiselle CG, Foulkes WD, Wong N. Cultural aspects of healthy BRCA carriers from two ethnocultural groups. Qual Health Res. 2014;24:665–81.CrossRefPubMed
21.
Sharma P, Klemp JR, Kimler BF, Mahnken JD, Geier LJ, Khan QJ, et al. Germline BRCA mutation evaluation in a prospective triple-negative breast cancer registry: implications for hereditary breast and/or ovarian cancer syndrome testing. Breast Cancer Res Treat. 2014;145:707–14.CrossRefPubMedPubMedCentral
22.
23.
Chan PC, Wong BY, Ozcelik H, Cole DE. Simple and rapid detection of BRCA1 and BRCA2 mutations by Multiplex Mutagenically Separated PCR. Clinical Chemistry. 1999;45:1285–7.PubMed
24.
Bogdanova NV, Antonenkova NN, Rogov YI, Karstens JH, Hillemanns P, Dörk T. High frequency and allele-specific differences of BRCA1 founder mutations in breast cancer and ovarian cancer patients from Belarus. Clin Genet. 2010;78(4):364–72.CrossRefPubMed
25.
Gaj P, Kluska A, Nowakowska D. High frequency of BRCA1 founder mutations in Polish women with nonfamilial breast cancer. Familial Cancer. 2012;11:623–8.CrossRefPubMed
26.
Sokolenko AP, Mitiushkina NV, Buslov KG, Bit-Sava EM, Iyevleva AG, Chekmariova EV, et al. High frequency of BRCA1 5382insC mutation in Russian breast cancer patients. Eur J Cancer. 2006;42:1380–4.CrossRefPubMed
27.
Edlich RF, Winters KL, Lin KY. Breast cancer and ovarian cancer genetics. J Long Term Eff Med Implants. 2005;15(5):533–45.CrossRefPubMed
Metadata
Title
The frequency of BRCA1 founder mutation c.5266dupC (5382insC) in breast cancer patients from Ukraine
Authors
Ielizaveta Gorodetska
Svitlana Serga
Natalia Levkovich
Tetiana Lahuta
Ludmila Ostapchenko
Serhyi Demydov
Nikolay Anikusko
Valeriy Cheshuk
Ivan Smolanka
Svitlana Sklyar
Serhyi Polenkov
Oleksander Boichenko
Iryna Kozeretska
Publication date
01-12-2015
Publisher
BioMed Central
Published in
Hereditary Cancer in Clinical Practice / Issue 1/2015
Electronic ISSN: 1897-4287
DOI
https://doi.org/10.1186/s13053-015-0040-3

Other articles of this Issue 1/2015

Hereditary Cancer in Clinical Practice 1/2015 Go to the issue

Research

Patient experiences living with pancreatic cancer risk

Research

Tumour spectrum in non-BRCA hereditary breast cancer families in Sweden

Case report

High-grade endometrial stromal sarcoma as the initial presentation of an adult patient with Peutz-Jeghers Syndrome: a case report

Research

Ten modifiers of BRCA1 penetrance validated in a Norwegian series

Research

Decisions about prophylactic gynecologic surgery: a qualitative study of the experience of female Lynch syndrome mutation carriers

Research

The c.470 T > C CHEK2 missense variant increases the risk of differentiated thyroid carcinoma in the Great Poland population
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits